• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一例顽固性化脓性汗腺炎:生物制剂、抗生素及手术治疗联合应用成功治愈

A Recalcitrant Case of Hidradenitis Suppurativa: Successful Combination of Biologic, Antibiotic, and Surgical Therapy.

作者信息

Arif Nawa, Schneider-Burrus Sylke

机构信息

Klinik für Dermatologie, Venerologie and Allergologie, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Center for Dermatosurgery, Havelklinik Berlin, Berlin, Germany.

出版信息

Case Rep Dermatol. 2025 Jun 11;17(1):268-273. doi: 10.1159/000546384. eCollection 2025 Jan-Dec.

DOI:10.1159/000546384
PMID:40657283
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12252370/
Abstract

INTRODUCTION

Hidradenitis suppurativa (HS), or acne inversa, is a chronic inflammatory skin disease that leads to painful nodules, abscesses, and fistulas.

CASE PRESENTATION

This case describes the treatment of a 49-year-old male patient with progressive and massively inflamed HS for 20 years who also suffered from heart failure (NYHA II-III, EF 35-40%) and hypochromic microcytic anaemia (Hb 7.8 g/dL). Upon presentation, he was suffering from fatigue and severe pain (8-9/10, NRS). Due to prolonged immobility, knee and hip joint contractures with extension deficits were present. At the initial presentation, communicating, and purulent sinus tracts were observed bilaterally from the gluteal to femoral region and perianal area. Hurley score III, HS-PGA score: very severe, Dermatology Life Quality Index (DLQI) score: 19, ISH4 score: severe (16). Under adalimumab s.c. 40 mg/week combined with clindamycin (300 mg bd), the condition had worsened. The patient was admitted to the hospital for i.v. administration of ertapenem 1 g/day for 14 days in preparation for sinus tract resection. With an Hb level of 7.8 g/dL, the patient received iron carboxymaltose and erythropoietin. After a significant reduction in inflammatory markers (leukocytes 17.11/nL to 7.42/nL), a large excision of the sinus tracts was performed bilaterally in the gluteal region and left femoral area. Following 4 weeks of wound granulation, split-thickness skin grafting was performed. The knee and hip joint contractures improved with intensive physiotherapy. After surgery, the patient received antibiotic therapy with clindamycin, rifampicin, and metronidazole (clindamycin 600 mg, rifampicin 300 mg, metronidazole 500 mg, each p.o. 2×/day). In parallel, anti-inflammatory therapy with secukinumab 300 mg s.c. twice a month was initiated. Over the following 3 months, no progression or recurrence occurred. Quality of life and pain levels improved significantly under the therapy (DLQI from 19 to 10, pain from 8 to 9 to 3/10 NRS).

CONCLUSION

In extensive cases of HS, a combination of surgical and conservative therapy is necessary. We demonstrate that severe cases can be successfully treated with a combination of antibiotic, anti-inflammatory, and surgical therapy.

摘要

引言

化脓性汗腺炎(HS),又称反向性痤疮,是一种慢性炎症性皮肤病,可导致疼痛性结节、脓肿和瘘管。

病例介绍

本病例描述了一名49岁男性患者的治疗情况,该患者患有进行性且严重发炎的HS达20年,同时还患有心力衰竭(纽约心脏协会II - III级,射血分数35 - 40%)和低色素小细胞贫血(血红蛋白7.8 g/dL)。就诊时,他感到疲劳且疼痛剧烈(数字评分量表8 - 9/10)。由于长期不动,出现了膝关节和髋关节挛缩伴伸展功能障碍。初诊时,双侧从臀区至股部区域及肛周可见相通的脓性窦道。Hurley评分III级,HS - PGA评分:非常严重,皮肤病生活质量指数(DLQI)评分:19,ISH4评分:严重(16)。在皮下注射阿达木单抗40 mg/周联合克林霉素(300 mg,每日两次)治疗后,病情恶化。患者入院接受静脉注射厄他培南1 g/天,共14天,为窦道切除术做准备。鉴于血红蛋白水平为7.8 g/dL,患者接受了羧基麦芽糖铁和促红细胞生成素治疗。炎症标志物显著降低(白细胞从17.11/μL降至7.42/μL)后,在双侧臀区和左股部区域对窦道进行了大面积切除。伤口肉芽形成4周后,进行了中厚皮片移植。通过强化物理治疗,膝关节和髋关节挛缩情况有所改善。术后,患者接受了克林霉素、利福平和甲硝唑的抗生素治疗(克林霉素600 mg,利福平300 mg,甲硝唑500 mg,均口服,每日两次)。同时,开始每月两次皮下注射司库奇尤单抗300 mg进行抗炎治疗。在接下来的3个月里,病情没有进展或复发。治疗期间,生活质量和疼痛程度显著改善(DLQI从19降至10,疼痛程度从数字评分量表8 - 9降至3/10)。

结论

在HS的广泛病例中,手术和保守治疗相结合是必要的。我们证明,严重病例可通过抗生素、抗炎和手术治疗相结合成功治愈。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6472/12252370/51ba416875f7/cde-2025-0017-0001-546384_F02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6472/12252370/38c8ed9906ba/cde-2025-0017-0001-546384_F01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6472/12252370/51ba416875f7/cde-2025-0017-0001-546384_F02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6472/12252370/38c8ed9906ba/cde-2025-0017-0001-546384_F01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6472/12252370/51ba416875f7/cde-2025-0017-0001-546384_F02.jpg

相似文献

1
A Recalcitrant Case of Hidradenitis Suppurativa: Successful Combination of Biologic, Antibiotic, and Surgical Therapy.一例顽固性化脓性汗腺炎:生物制剂、抗生素及手术治疗联合应用成功治愈
Case Rep Dermatol. 2025 Jun 11;17(1):268-273. doi: 10.1159/000546384. eCollection 2025 Jan-Dec.
2
Interventions for hidradenitis suppurativa.化脓性汗腺炎的干预措施。
Cochrane Database Syst Rev. 2015 Oct 7;2015(10):CD010081. doi: 10.1002/14651858.CD010081.pub2.
3
Bimekizumab Impact on Patient-Reported Outcomes in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II.比美吉珠单抗对中度至重度化脓性汗腺炎患者报告结局的影响:BE HEARD I&II的48周汇总结果
Dermatol Ther (Heidelb). 2025 Jul 13. doi: 10.1007/s13555-025-01465-4.
4
Efficacy and Durability of Intravenous Ertapenem Therapy for Recalcitrant Hidradenitis Suppurativa.静脉注射厄他培南治疗顽固性化脓性汗腺炎的疗效和持久性。
JAMA Dermatol. 2024 Mar 1;160(3):312-318. doi: 10.1001/jamadermatol.2023.6201.
5
Validation of the real-world application of the Hidradenitis Suppurativa Quality of Life (HiSQOL) score to adults with hidradenitis suppurativa.化脓性汗腺炎生活质量(HiSQOL)评分在成年化脓性汗腺炎患者真实世界应用中的验证。
Br J Dermatol. 2025 Jan 24;192(2):261-268. doi: 10.1093/bjd/ljae367.
6
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.
7
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状荟萃分析。
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
8
Psychometric validation and interpretation thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL©) questionnaire using pooled data from the phase III BE HEARD I & II trials of bimekizumab in hidradenitis suppurativa.使用比美吉珠单抗治疗化脓性汗腺炎的III期BE HEARD I和II试验的汇总数据,对化脓性汗腺炎生活质量(HiSQOL©)问卷进行心理测量学验证和解释阈值分析。
Br J Dermatol. 2025 Jun 20;193(1):93-104. doi: 10.1093/bjd/ljaf067.
9
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
10
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.

本文引用的文献

1
Management of patients with hidradenitis suppurativa during COVID-19 vaccination: an experience from southern Italy. Comment on: 'Evaluating the safety and efficacy of COVID-19 vaccination in patients with hidradenitis suppurativa'.化脓性汗腺炎患者在新冠疫苗接种期间的管理:来自意大利南部的经验。评论:“评估化脓性汗腺炎患者接种新冠疫苗的安全性和有效性”
Clin Exp Dermatol. 2022 Nov;47(11):2026-2028. doi: 10.1111/ced.15306. Epub 2022 Aug 4.
2
Hidradenitis Suppurativa Is Characterized by Dysregulation of the Th17:Treg Cell Axis, Which Is Corrected by Anti-TNF Therapy.化脓性汗腺炎的特征是Th17:调节性T细胞轴失调,抗TNF治疗可纠正这一失调。
J Invest Dermatol. 2017 Nov;137(11):2389-2395. doi: 10.1016/j.jid.2017.05.033. Epub 2017 Jun 23.
3
Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents.在化脓性汗腺炎患者中,白细胞介素(IL)-17 血清水平升高:提示抗 IL-17 药物治疗的意义。
J Am Acad Dermatol. 2017 Apr;76(4):670-675. doi: 10.1016/j.jaad.2016.10.042. Epub 2016 Dec 29.
4
Low-dose systemic corticosteroid treatment for recalcitrant hidradenitis suppurativa.低剂量全身性皮质类固醇治疗顽固性化脓性汗腺炎。
J Am Acad Dermatol. 2016 Nov;75(5):1059-1062. doi: 10.1016/j.jaad.2016.06.001.
5
Clinical practice. Hidradenitis suppurativa.临床实践。化脓性汗腺炎。
N Engl J Med. 2012 Jan 12;366(2):158-64. doi: 10.1056/NEJMcp1014163.